Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.32 |
| ▸ | KAT7 | O95251 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34464940 | 1.00 | USP30 (0.33) | USP30CYP8B1KAT7ALOX5APFEN1 | |
| SCHEMBL35212040 | 0.90 | PARP1 (0.36) | USP30KAT7ALOX5APFEN1PARP1 | |
| SCHEMBL35212333 | 0.90 | PARP1 (0.36) | USP30KAT7ALOX5APFEN1PARP1 | |
| SCHEMBL35212337 | 0.87 | SCN9A (0.35) | USP30PARP1SCN9ALMNATSHR | |
| SCHEMBL34465074 | 0.86 | USP30 (0.33) | USP30CNR1 | |
| SCHEMBL34465124 | 0.86 | USP30 (0.33) | USP30CNR1 | |
| SCHEMBL34465015 | 0.85 | ALOX5AP (0.32) | USP30ALOX5APFEN1PARP1CNR1 | |
| SCHEMBL34465016 | 0.81 | KAT6A (0.30) | — | |
| SCHEMBL34465011 | 0.80 | — | — | |
| SCHEMBL34466527 | 0.78 | OPRK1 (0.35) | USP30SCN9ALMNATSHRNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108510-A1 | PYRAZOLYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108510-A1 | PYRAZOLYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | CGAS, GBA3, CYP11B2 | USP30 3974/4885CYP8B1 540/4885KAT7 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.